Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

RenovoRx Collaborates with Imugene

Friday, July 21, 2023

RenovoRx and Imugene have announced a strategic research collaboration aimed at optimising the delivery of Imugene's oncolytic virus therapy using RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform. 

The collaboration aims to explore the feasibility and benefits of delivering Imugene's CF33 oncolytic virus technology trans-arterially using RenovoRx's TAMP platform. Moreover, this collaboration focus to target difficult-to-access tumours, such as those found in pancreatic and liver cancers. 

By combining Imugene's CF33 oncolytic virus technology with RenovoRx's TAMP therapy platform, aim to address the challenges associated with treating tumours in regions that are hard to reach using traditional administration methods. In such difficult-to-access tumours, dense fibrous tissue and limited blood vessel supply have been known to hinder the uptake of therapy.

This joint effort represents a significant milestone to expand the treatment pipeline from solely addressing locally advanced disease to potentially treating metastatic disease with immunotherapy.

By combining RenovoRx's precise drug delivery system with Imugene's CF33 oncolytic virus platform, there is the potential to enhance the treatment of challenging cancers and offer new hope to patients facing difficult-to-treat tumours.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024